We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Tilray Inc is a drug manufacturers-specialty & generic business with stocks listed in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$11 – a decrease of 5.66% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$5.25 - US$55.01 |
|---|---|
| 50-day moving average | US$11.4909 |
| 200-day moving average | US$14.9994 |
| Target price | US$13.95 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.166 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $11
| 3 months (2021-07-26) | -19.71% |
|---|---|
| 6 months (2021-04-26) | -38.38% |
| 1 year (2020-10-26) | 87.71% |
|---|---|
| 2 years (2019-10-25) | -53.53% |
| 3 years (2018-10-26) | -89.82% |
Valuing Tilray stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tilray's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tilray's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9 million (£0.0 million).
The EBITDA is a measure of a Tilray's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$563.6 million |
|---|---|
| Gross profit TTM | US$123.2 million |
| Return on assets TTM | -1.67% |
| Return on equity TTM | -12.02% |
| Profit margin | -66.49% |
| Book value | 9.588 |
| Market capitalisation | US$5.1 billion |
TTM: trailing 12 months
There are currently 38.2 million Tilray shares held short by investors – that's known as Tilray's "short interest". This figure is 1.8% down from 39.0 million last month.
There are a few different ways that this level of interest in shorting Tilray shares can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray shares currently shorted divided by the average quantity of Tilray shares traded daily (recently around 16.1 million). Tilray's SIR currently stands at 2.37. In other words for every 100,000 Tilray shares traded daily on the market, roughly 2370 shares are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray shares, or, against the total number of tradable Tilray shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Tilray shares in existence, roughly 80 shares are currently held short) or 0.0848% of the tradable shares (for every 100,000 tradable Tilray shares, roughly 85 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months.
Over the last 12 months, Tilray's shares have ranged in value from as little as US$5.25 up to US$55.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.6198. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
